United States: Six Key Follow-Up Questions Asked By Congress In 340B Hearing (Video)

Last Updated: November 2 2017
Article by Ellyn Sternfield

Earlier this month the House Energy and Commerce Committee's subcommittee on Government Oversight and Investigations held its second hearing on the 340B Drug Discount Program. The hearing followed on the heels of a July 18th hearing in which officials from the Health Resources and Services Administration (HRSA), the Government Accountability Office (GAO), and the Department of Health and Human Services Office of Inspector General (HHS-OIG) testified about the challenges faced in overseeing the 340B Program.

This hearing was called Examining How Covered Entities Utilize the 340B Drug Pricing Program. Representatives of five different covered entities were asked to address three questions in their testimony:

  • How much do 340B Covered Entities save when purchasing 340B drugs?
  • How are those savings tracked?
  • How are those savings used?

However, it was the follow-up questions from subcommittee and committee members that may indicate where Congress is headed in legislating changes to the 340B Program.

Covered Entity Testimony

The committee asked a cross-section of covered entity representatives to testify: one from a Federally Qualified Health Center (FQHC) in South Carolina, one from a Ryan White HIV/AIDS Program grantee based in the Midwest, one from a Disproportionate Share Hospital (DSH) system that serves rural areas of North Carolina, and two from large regional DSHs that largely serve urban populations in Maryland and Georgia.

All of the witnesses acknowledged that their entities save on drug costs through participation in the 340B Program. The three DSH representatives testified that because of 340B savings, they can provide considerable uncompensated care to patients. They also testified about additional services they are able to provide, such as treatment centers for abuse victims, wrap-around services for those with chronic conditions, and preventative health screenings. The FQHC and the Ryan White Program representatives testified that unlike the DSHs, their use of 340B income is restricted to funding pharmacy services for their patients.

Six Key Follow-Up Questions

Participating legislators uniformly voiced support for the 340B Program and noted that covered entities appeared to be appropriately using their savings to expand access to care. However, follow-up questions probed areas of concern. While dozens of questions were posed, six appear to be key:

1. Are 340B "savings" calculated in a consistent manner?

It appears there are inconsistencies in how covered entities calculate 340B savings. Of the testifying witnesses, three stated that their facilities determine 340B savings by calculating the difference between the actual 340B purchase price and the Group Purchasing Organization (GPO) purchase price. One covered entity defined savings as the net margin after the 340B drugs were dispensed/reimbursed. And another covered entity described its savings as being based on its contract pharmacies' costs.

2. Are 340B savings earmarked for particular programs, and what would be the effect on those programs if the amount of savings was reduced?

The FQHC and Ryan White representatives testified that based on HRSA regulations, they are limited in how they can use income derived from 340B; 340B revenues are used to fund pharmacy costs for their patients and are appropriately reported in their budgets and financial reporting to HRSA. Loss of 340B revenue would reduce those pharmacy services.

The DSH representatives acknowledged that, in practice, 340B revenue is a line item in budgeting and not specifically earmarked. However, they noted that the revenue is what helps fund charity care and a variety of "additional" services earlier described; reduction in 340B revenue would necessitate reductions in the level of charity care provided and possibly eliminate additional programs such as wrap-around services for those with chronic conditions and preventative health screenings. That testimony led to a rebuke from committee Chair Greg Walden, who said he was surprised that the facilities would not first consider rolling back overhead costs, reducing executive bonuses, or curtailing building expansions, but would immediately roll back patient care if 340B revenue was decreased.

3. How do DSHs measure "charity" or "uncompensated" care?

The three DSH representatives all stated that the amount of charity or uncompensated care they provide far outpaces 340B Program revenue. But committee Chair Walden questioned how that "charity" or "uncompensated" care is measured. Does the amount reported by each facility actually represent the cost of the care provided to uninsured individuals who are not billed for the care? Or does the stated amount include care provided to insured individuals, including government beneficiaries, where reimbursement rates fall below the billed amount for the services provided. He received no detailed responses.

4. Describe CEO salaries, and facility assets/net income?

Representative Tim Walberg asked the witnesses to confirm information about their CEO's reported salary (ranging from a low of $190,000 to a high of $2.8 million), and their entity's reported net assets and net income. For the three DSHs, net assets ranged from $1 billion to $1.4 billion and net income ranged from $81 million to $157 million.

5. Do uninsured or self-pay patients get 340B drugs at the 340B discount prices? And to what extent do covered entities refer uninsured patients to patient assistance programs?

Representative Ryan Costello asked the witnesses whether uninsured patients treating at their facilities can access 340B drugs at or below the 340B discount prices. The FQHC and Ryan White representatives indicated that under applicable HRSA rules, they must make 340B drugs available to their self-pay patients. The three DSH representatives testified that their facilities each operate Medication or Pharmacy Assistance Programs to facilitate access to drugs for qualified patients.

Representative Costello followed up by asking the witnesses if they also connected patients to charitable patient assistance programs (PAPs) offered by manufacturers of specific drugs, or offered by third party charities that help patients afford the cost of care, including drug costs. All of the witnesses indicated that facility staff do help patients access PAPs which offer medication assistance, but could not provide specific information on the numbers of patients who receive PAP assistance.

6. Have DSHs leveraged 340B revenue through acquisition of suburban outpatient oncology clinics?

Multiple questions were raised regarding urban DSH purchases of suburban outpatient oncology clinics, which allowed the hospitals to dispense expensive oncology drugs obtained at 340B discounts to the largely insured patients of these clinics.

In response to questions raised by Representative Carter, one of the DSH representatives stated that the purchase of oncology clinics was part of a strategy to maximize integrated care for its patients. Representative Brooks questioned whether because of the purchases, patients were now charged facility fees for treatment received at the clinics. And Representative Collins noted that a hospital qualifies for DSH status based on its inpatient patient mix, meaning that the purchase of suburban outpatient clinics has no impact on a hospital's DSH status.

What Wasn't Asked

Interestingly, there was only one fleeting reference to the CMS proposal to reduce Medicare Part B reimbursement for 340B drugs, scheduled to go into effect on January 1, 2018. However there were multiple references to concerns about 340B contract pharmacies, and indications that there would be a third congressional hearing on 340B to address those concerns.

What it Mean?

It appears that there will be at least one more 340B hearing before we may see any proposals for legislation.

If there is legislation, one thing is clear: there is bipartisan support for continuing the 340B Program. But the questions asked in this hearing, combined with the testimony provided at the July 18th hearing, appear to indicate some consensus for changes to the 340B Program, including imposing covered entity reporting requirements for 340B savings, a standardized methodology for calculating those savings, and covered entity reporting requirements on how those savings are used.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Ellyn Sternfield
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions